Notice of Revision to Earnings Guidance

Overview of Revision to Earnings Guidance

Fuso Pharmaceutical Industries,Ltd. has revised upward its earnings guidance for the second quarter of the fiscal year ending March 2027. Net sales are expected to exceed the previous forecast, reaching 32,300 million yen; operating income is projected at 1,700 million yen; ordinary income at 1,400 million yen; and interim net income at 1,000 million yen. Interim net income per share is 117.15 yen, an improvement from the prior forecast. Reasons for the revision include that, although there was a negative impact from drug price revisions, sales remained firm due to the effectiveness of promotional activities, and some cost increases were deferred to the second half. The full-year forecast is currently under review and will be announced on November 11.

Full-Year Outlook and Points to Note

Factors contributing to the interim upside include the containment of some expected increases in raw material costs and the impact of new licensing agreements. The full-year earnings forecast is under review and will be announced at the Q2 results presentation on November 11. Depending on future market trends, foreign exchange movements, and raw material trends, there remains a risk of further revisions.